Physician profile
Geetha Vedula
NPI 1700048501
$20,312.01
in general payments reported to CMS, 2019-2025
26 companies · $3,834 in 2025
The $3,834 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,833 · 2020: $2,571 · 2021: $2,890 · 2022: $1,244 · 2023: $3,359 · 2024: $2,581 · 2025: $3,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,002 · Travel and Lodging: $763 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,002.06 |
| Travel and Lodging | $763.48 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,352.75 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Johnson & Johnson Surgical Vision, INC. | $2,838.08 | 2019-2023 | Tecnis Iol |
| Abbvie INC. | $2,666.15 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Lumigan |
| New World Medical,INC. | $2,029.12 | 2022-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Bausch & Lomb Americas INC. | $1,579.99 | 2023-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Carl Zeiss Meditec, INC. | $1,465.04 | 2020 | |
| Sight Sciences, INC. | $1,275.60 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Biotissue Holdings INC. | $1,254.54 | 2019-2025 | |
| Allergan, INC. | $1,156.98 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $648.24 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $527.79 | 2019-2025 | |
| Horizon Therapeutics Plc | $384.31 | 2021 | |
| Glaukos Corporation | $379.25 | 2019-2023 | Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $277.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $82.84 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $72.20 | 2019 | |
| Harrow Eye, LLC | $66.28 | 2025 | Vevye |
| Amgen INC. | $54.44 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $37.40 | 2024 | Acthar |
| Eyevance Pharmaceuticals LLC | $29.86 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $26.56 | 2024 | Xdemvy |
| Akorn, INC. | $24.10 | 2019 | |
| Oyster Point Pharma, INC. | $23.87 | 2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $22.29 | 2019 | |
| Dompe US, INC. | $21.96 | 2022 | |
| Thea Pharma INC. | $14.76 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geetha Vedula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.